TickerFacts.

Alpha Teknova, Inc. (TKNO): Long-Term Debt

Annual figures by period end, from SEC filings.

$13.12M
As of 2025-12-31
$13.22M
As of 2026-06-30
-15.8%
3-year compound annual growth
$21.98M2020-12-31: $02021-12-31: $11.87M2022-12-31: $21.98M2023-12-31: $13.25M2024-12-31: $9.44M2025-12-31: $13.12M$13.12M
2020-12-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$13.12M+39.0%2026-03-02, Balance as of period end
2024-12-31$9.44M-28.7%2026-03-02, Balance as of period end
2023-12-31$13.25M-39.7%2025-03-07, Balance as of period end
2022-12-31$21.98M+85.1%2024-03-27, Balance as of period end
2021-12-31$11.87Mn/a2023-03-30, Balance as of period end
2020-12-31$0n/a2022-03-18, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
Alpha Teknova, Inc. (TKNO)2025-12-31$13.12M+39.0%
Immucell Corp (ICCC)2025-12-31$9.10Mn/a
Aspira Women's Health Inc. (AWHL)2025-12-31$1.28M-15.3%
Myriad Genetics Inc (MYGN)2025-12-31$119.90Mn/a
Volitionrx Ltd (VNRX)2025-12-31$6.71M+39.4%
QuidelOrtho Corp (QDEL)2025-12-28$2.70B+8.4%
Idexx Laboratories Inc (IDXX)2025-12-31$450.00M-27.2%

Compare TKNO, ICCC, AWHL, MYGN side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗